The Top Five Pharma Stories Of 2023
The biopharma new year begins as the J.P. Morgan Healthcare Conference ends so here in no particular order, we take a look at five of the biggest stories of 2023, once again a year of highs and lows for the industry.
You may also be interested in...
CMS’ latest update to the list of products subject to inflation rebates in the Part B brings the total number of different products that will owe rebates in the first year of the new penalty to 64. The headlines about big savings do not match the reality of very modest liabilities for the affected manufacturers.
With the White House putting a spotlight on US shortages of their new RSV monoclonal antibody, Sanofi and AstraZeneca can take some solace that the negative headlines stem from unexpectedly high demand and easier reimbursement for the immunization than the companies’ predicted.
The recent ASH meeting began with US FDA approvals of the first genetic medicines for sickle cell disease, but doctors and biopharma companies still see a need for new oral therapies and other options.